National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Omalizumab (Xolair®) is indicated as an add-on therapy for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment. 

Rapid Review

Commenced Completed Outcome
25/03/2014 25/04/2014 Full Pharmacoeconomic Evaluation Not Recommended for this indication.